Nanjing Well Pharmaceutical Co Ltd (603351) — Cash Flow-to-Debt Ratio
Nanjing Well Pharmaceutical Co Ltd (603351) has a Cash Flow-to-Debt Ratio of 0.08x as of September 2025, meaning its operating cash flow of CN¥69.51 Million could theoretically repay 0% of its total liabilities (CN¥819.31 Million) in one year. See 603351 financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Nanjing Well Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Nanjing Well Pharmaceutical Co Ltd across 12 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Nanjing Well Pharmaceutical Co Ltd.
Annual Cash Flow-to-Debt Ratio for Nanjing Well Pharmaceutical Co Ltd (2014–2025)
Year-by-year debt coverage analysis for Nanjing Well Pharmaceutical Co Ltd. Check how high is Nanjing Well Pharmaceutical Co Ltd's earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.30x | CN¥238.24 Million | CN¥791.01 Million | ▼ -8.6% |
| 2024 | 0.33x | CN¥221.79 Million | CN¥672.72 Million | ▲ +88.2% |
| 2023 | 0.18x | CN¥120.24 Million | CN¥686.22 Million | ▲ +5.4% |
| 2022 | 0.17x | CN¥108.99 Million | CN¥655.76 Million | ▲ +757.0% |
| 2021 | -0.03x | CN¥-11.54 Million | CN¥456.01 Million | ▼ -109.1% |
| 2020 | 0.28x | CN¥93.30 Million | CN¥336.75 Million | ▼ -53.6% |
| 2019 | 0.60x | CN¥129.69 Million | CN¥217.06 Million | ▲ +81.4% |
| 2018 | 0.33x | CN¥63.76 Million | CN¥193.59 Million | ▼ -10.9% |
| 2017 | 0.37x | CN¥71.27 Million | CN¥192.73 Million | ▼ -54.9% |
| 2016 | 0.82x | CN¥128.18 Million | CN¥156.25 Million | ▲ +95.2% |
| 2015 | 0.42x | CN¥81.14 Million | CN¥193.01 Million | ▲ +0.8% |
| 2014 | 0.42x | CN¥74.62 Million | CN¥178.94 Million | — |